1005 Sleep Disturbances In Opioid Dependent Patients On Buprenorphine- Gender Differences. (27th April 2018)

• Record Type: Journal Article
• Authors: Basappa Krishnamurthy, V; Coffey, A; Sanjay, Y; Singh, J; Kong, L; Fernandez Mendoza, J; Vgontzas, A; Bixler, E; Roger, M
• Is Part Of: Sleep. Volume 41(2018)Supplement 1
• Page Start: A372
• Page End: A372
• Publication Date: 2018-04-27
• Subjects: Sleep -- Physiological aspects -- Periodicals; Sleep disorders -- Periodicals; Sommeil -- Aspect physiologique -- Périodiques; Sommeil, Troubles du -- Périodiques; Sleep disorders; Sleep -- Physiological aspects; Sleep -- physiological aspects; Sleep Wake Disorders; Psychophysiology; Electronic journals; Periodicals; 616.8498
• DOI: 10.1093/sleep/zsy061.1004
• Languages: English
• ISSNs: 0161-8105

Abstract

Abstract: Introduction: Sleep disturbances are common in opioid use disorder (OUD) patients on buprenorphine. The aim of the study is to examine gender differences in the prevalence and factors associated with sleep disturbances in patients with OUDs on buprenorphine. Methods: A total of 219 patients with OUDs on buprenorphine (35 ± 9.5 years, 49.3% women, 80% Caucasian) were recruited from a buprenorphine maintenance program in central Pennsylvania. Subjects completed a sociodemographic survey and the Pittsburgh Sleep Quality Index (PSQI). We used chi-square tests, t-tests, and Mann-Whitney U tests to compare demographics, sleep disturbances, and PSQI composite scores between men and women. Stepwise logistic regression analysis was performed to determine factors associated with poor sleep quality in men and women separately. Results: Women were more likely to report moderate-to-severe depression (42 %) and anxiety (53%) and to seek treatment for mental health issues (39 %) than men (24%, 36% and 19%, respectively, all Ps<0.01). Men had longer duration of opioid dependence (128 ± 102 months) and frequent rehabilitation hospitalizations (3 ± 3.5) than women (88 ± 66 months, and 2 ± 2 respectively, all Ps<0.01). Women had marginally longer duration of abstinence (33 ± 46 months) and adherence to medication treatment (19 ± 28 months) on buprenorphine than men (23 ± 31 months and 13 ± 19 months respectively, all Ps<0.10). Women had higher total PSQI scores (10.7 ± 4.8) and more frequent poor sleep quality (PSQI>5) (82%) than men (8.7 ± 4.3 and 69% respectively, p<0.05). In men, anxiety severity (OR=1.9, p=0.03) was independently associated with poor sleep quality. In women, age (OR=1.2, p=0.01) anxiety severity (OR=3.2, p=0.005) worsening sleep with opioid use (OR=6.3, p=0.008) were independently associated with poor sleep quality. Conclusion: Similar to the general population, women with OUDs on buprenorphine are more likely to have severe and frequent sleep disturbances than men. Age, presence of comorbid anxiety and onset of insomnia with opioid use may help predict sleep disturbance in women with OUDs on buprenorphine. Recognizing and treating sleep disturbances as well as anxiety in men and women with OUDs on buprenorphine should be a target for relapse prevention. Support (If Any): Department of Psychiatry, Penn State College of Medicine.